Overview
Markus Kreuz practices in Leipzig, Germany. Mr. Kreuz is rated as an Experienced expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).
His clinical research consists of co-authoring 61 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- B-Cell LymphomaMr. Kreuz isDistinguished. Learn about B-Cell Lymphoma.
- Burkitt LymphomaMr. Kreuz isDistinguished. Learn about Burkitt Lymphoma.
- Advanced
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Non-Hodgkin LymphomaMr. Kreuz isAdvanced. Learn about Non-Hodgkin Lymphoma.
- Experienced
- Cutaneous Lupus Erythematosus (CLE)Mr. Kreuz isExperienced. Learn about Cutaneous Lupus Erythematosus (CLE).
- Follicular LymphomaMr. Kreuz isExperienced. Learn about Follicular Lymphoma.
- Kyasanur Forest DiseaseMr. Kreuz isExperienced. Learn about Kyasanur Forest Disease.
- MononucleosisMr. Kreuz isExperienced. Learn about Mononucleosis.
- Multiple MyelomaMr. Kreuz isExperienced. Learn about Multiple Myeloma.
- Neurotoxicity SyndromesMr. Kreuz isExperienced. Learn about Neurotoxicity Syndromes.